# Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

> **NCT00812071** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** RiVax

## Key facts

- **NCT ID:** NCT00812071
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-01
- **Final completion:** 2012-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812071, "Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00812071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*